Hodgkin Lymphoma Clinical Trials in Bethesda, Maryland
12 recruitingBethesda, Maryland
Showing 1–12 of 12 trials
Recruiting
Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled399 locationsNCT05675410
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 1Phase 2
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Phase 1Phase 2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaLymphoma+1 more
National Cancer Institute (NCI)155 enrolled1 locationNCT03223610
Recruiting
Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaLymphoma+1 more
National Cancer Institute (NCI)55 enrolled1 locationNCT04739813
Recruiting
Phase 1
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Non-Hodgkin LymphomaPlasmablastic LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI)25 enrolled1 locationNCT05389423
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Non-Hodgkin LymphomaBacterial InfectionsHypogammaglobulinemia+2 more
Grifols Therapeutics LLC386 enrolled61 locationsNCT05645107
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774
Recruiting
Phase 1
Studying TAK-243 in Patients With Advanced Cancer
Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+3 more
National Cancer Institute (NCI)95 enrolled1 locationNCT06223542
Recruiting
Phase 1
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Hodgkin LymphomaAMLMDS+8 more
Therapeutic Advances in Childhood Leukemia Consortium54 enrolled31 locationsNCT05476770